En vivo
FierceBiotechAACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave risesFierceBiotechRacing toward first FDA nod for autoimmune CAR-T, Kyverna bolsters lead with full SPS datasetFierceBiotechRoche unpacks death imbalance, secondary endpoints in phase 3 multiple sclerosis trialsLonza NewsProject Hope Foundation receives $50K donation from Lonza Capsugel - Greenville JournalFierceBiotechPulnovo Medical scores $100M in finance round led by MedtronicIlluminaCSR News Feed | Explore the latest corporate social responsibility news from Illumina - IlluminaLonza NewsLonza Group AG stock (CH0013841017): Why biopharma contract manufacturing now matters more for U.S. - AD HOC NEWSDandong Aolong Radiative Instrument Group Co.,LtdWho Are the Top Competitors in the Bulk Petroleum and Chemical Storage Market Today - Weekly VoiceDandong Aolong Radiative Instrument Group Co.,LtdCompetitive Developments in the Industrial X-Ray Market: Strategies to Watch - Weekly VoiceIlluminaCSR News Feed | Explore the latest corporate social responsibility news from Illumina - Illumina10x Genomics BlogIs Atera’s New Spatial Biology Platform Altering The Investment Case For 10x Genomics (TXG)? - simplywall.stBrady CorporationMilwaukee’s Brady Corp Buying Honeywell Division - Seehafer News
BioPharma Dive 7 ene 2026

GSK, Ionis claim study success for RNA-based hepatitis B drug

GSK, Ionis claim study success for RNA-based hepatitis B drug

Original
Contenido no disponible. Consulta la fuente original.